How is the data centre industry evolving to meet the challenges of AI, sustainability, and energy security? In this episode of Built Environment Matters, Jaimie Johnston MBE speaks with Lincoln Wood, Director of Design at Edged.

As AI workloads push rack densities to 150 kW and beyond, data centre design is inverting – from white space outward to infrastructure inward. MEP Director Michael Hope-Jones argues the industry needs to stop chasing the future and start building present-enabling infrastructure that can adapt as requirements crystallise.

What happens when drug discovery leaders, big pharma, regulators, AI solution providers, and venture capital sit in the same room? Bryden Wood's Accelerate roundtable on AI and pharmaceutical manufacturing surfaced a clear consensus: the hype is in the wrong places – and we are not ambitious enough.

Professor John Dyson asks what it means to be human at a moment when AI is reshaping how we work, decide, and collaborate – drawing on philosophy, neuroscience, and a walk in the woods to argue that curiosity, ethics, and practical reasoning matter more now than ever.

Professor John Dyson builds an economic model to test what happens when pharmaceutical production scale gets it wrong. The results are striking – and largely ignored by industry. Understanding diseconomies of scale, he argues, could save billions and change how companies think about their entire product portfolio.

Solvents are costly, environmentally harmful, and heavily regulated – yet the pharmaceutical industry has no clear path to replacing them. This roundtable report from Bryden Wood's Accelerate Pharmaceuticals series captures what happens when the whole ecosystem comes together to confront the dilemma honestly.

Why are things the size they are? Professor John Dyson traces the logic of scale from mitochondria to mega-factories – and argues that nature solved this problem millions of years ago. The question is whether industry is paying attention.

What happens when competitors from across the data centre industry come together to share problems openly? Bryden Wood convened leaders from Google, Equinix, VIRTUS, Edged, and Digital Realty to confront the sector's most pressing challenges – from exponential rack density to power supply constraints and regulatory fragmentation across Europe.

As 2024 draws to a close, Professor John Dyson reflects on three unexpected sources of optimism – the values of the next generation, the quiet work of people already building a better world, and the profound humanity of strangers thrown together on an overcrowded train.

Gigafactories are among the most complex and time-critical buildings in the world. Adam Jordan, Bryden Wood's Asia-Pacific Lead, examines how DfMA can reduce cost and programme by 30% or more – and why getting the design right before prefabricating anything is the critical first step.

How do you stop a great pharmaceutical project concept from being ground down by the delivery process? In Part 2 of Pharma's Conundrum, Professor John Dyson sets out the principles of Integrated Project Delivery – and why shared value, not scope management, is the real measure of success.

The pharmaceutical industry assumes that once a project concept is agreed, iteration is a risk. Professor John Dyson argues the opposite – that emergence in design is inevitable, and that pretending otherwise destroys value. Part one of his Pharma's Conundrum series sets out a smarter approach to scheme design.